#RareDiseaseDay is a time to recognize those living with a rare disease and the scientific and clinical communities dedicated to finding new treatments. At Electra, we are proud to stand with you and remain dedicated to advancing ELA026 in the fight against #sHLH.

Today at #ASH25, results of the completed Phase 1b study of ELA026 for the treatment of secondary hemophagocytic lymphohistiocytosis (#sHLH) will be presented.  https://t.co/zZlNSrvWvN

Be sure to check out a new interview with our CEO Kathy Dong in Inside Precision Medicine. Kathy talks about #sHLH, a rare inflammatory disease, and the encouraging clinical trial results for ELA026. https://t.co/lJLZ7BNveT

Join us at #ASH2024 on December 9th, 2:45pm PT for an oral presentation on ELA026. We will be sharing clinical data from our completed phase 1b study of ELA026 in #sHLH. https://t.co/3DnmqAzzR4

#sHLH is a life-threatening disease with no approved treatments. #FastTrack designation underscores the urgent need for effective therapeutic options and accelerates our development path to make a transformative impact on patients and their families. https://t.co/X4pqBt6Z21

We're excited to announce orphan drug designation for ELA026, a first-in-class antibody therapy targeting SIRP with a novel mechanism of action to treat secondary HLH (sHLH). #sHLH https://t.co/RzD4Dxxrol

Electra's lead candidate, ELA026, shows promising results for improved survival in secondary HLH triggered by malignancy. Our phase 1b results presented at #EHA2024

New encouraging secondary #HLH treatment https://t.co/snlO5lCIZ9 Abhishek Maiti @MDAndersonNews #Leukemia @EHA_Hematology #EHA2024

ELA026 demonstrated a high overall response rate across a range of #sHLH patients. In patients with the poorest prognosis, those with malignancy-associated HLH, early treatment with ELA026 resulted in 100% ORR and improved survival. #EHA2024 https://t.co/aLsbpFdgk9

Clinical data for our lead candidate ELA026 is selected as 1 of 6 abstracts for the late-breaking oral session at #EHA2024. Data is from our ongoing Phase 1b study in patients with #sHLH, a life-threatening inflammatory disease. https://t.co/DHc7223ba6

We are delighted to have these exceptional leaders on our team: Dr. Graham Parry as CSO and Dr. Kim-Hien Dao as CMO. Their extensive experience and expertise in drug development will be invaluable at this time of great momentum for Electra. https://t.co/sfxO6WRnsT

We recently had the honor of hosting patient advocates who shared incredibly moving stories of their loved one’s journeys with #sHLH. Our team was inspired by their passion and dedication to raising awareness and finding a treatment.

#RareDiseaseDay is a time to acknowledge the remarkable resilience of individuals around the world living with rare conditions, as well as their dedicated family members and friends. #rarediseaseday2024 #RareDiseasesDay

Hope to see you at #ASH23 where we'll be presenting Phase 1b clinical data for our lead drug candidate ELA026 for secondary hemophagocytic lymphohistiocytosis (#sHLH), a life-threatening inflammatory disease. #Histiocytosis https://t.co/0BHgI8scdk

We’re excited to highlight ELA026, our antibody in the clinic for secondary hemophagocytic lymphohistiocytosis (#sHLH), in an oral presentation today during the Presidential Symposium at the Histiocyte Society Annual Meeting. #HSMtg2023 #Histiocytosis https://t.co/re4qg4lZDU

Join the Electra team in supporting #HistiocytosisAwareness month and recognizing people living with histiocytic disorders. We are committed to advancing ELA026 for the treatment of #sHLH. #HistioBlueRibbonRun, #histiorunchallenge, #histiocytosisawareness, #iknowhistio

We are honored to have been recognized as the Most Innovative Start-up Company at last night's 7th Annual #CitelineAwards! The judges made note of our collaborative research and educational work with trial sites in their evaluation of the nominees.

We're honored to have been selected by Citeline as one of the Most Innovative Start-up Companies in 2022 and will continue innovating for rare-disease patients. #CelebrateCiteline https://t.co/BwsM3c49Ca

For us, everyday is Rare Disease Day as we work to transform the treatment landscape for patients most in need. #ShareYourColours #RareDiseaseDay2023 #RareDisease

Without treatment, secondary hemophagocytic lymphohistiocytosis (sHLH) can rapidly progress to multi-organ failure and death. #MasteringSIRP https://t.co/XGCXETV6he